Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.
OBJECTIVE
To assess adherence to highly active antiretroviral therapies (HAART) in a cohort of French patients infected by HIV through injection drug use (IDU), and the impact on adherence of buprenorphine ambulatory drug maintenance treatment (DMT) which has been widely introduced since 1996.


METHODS
Adherence assessment at first visit after initiation of HAART in the MANIF2000 cohort study.


METHODS
Patient's face-to-face and self-administered questionnaires. Univariate and logistic regression adjusted odds ratios (OR) to compare characteristics of non-adherent versus adherent patients.


RESULTS
Of the 164 patients, 34.8% took less than 80% of the prescribed HAART doses during the previous week. Decrease in viral load titres after initiation of HAART was significantly lower among non-adherent patients. After adjustment by logistic regression, non-adherence was associated with younger age, alcohol consumption, frequency of negative life-events during the prior 6 months and active drug use. However, IDU in buprenorphine DMT reached higher levels of adherence (78.1%) than ex-IDU (65.5%), although this difference did not reach statistical significance.


CONCLUSIONS
Prescription of buprenorphine DMT may increase adherence to HAART among HIV-infected opiate-dependent patients. Reducing the negative impact of stressful life-events through psychosocial interventions should be considered, even for those who have stopped using drugs.
Moatti
J P
JP
INSERM Research Unit 379, Marseille, France.
Carrieri
M P
MP
Spire
B
B
Gastaut
J A
JA
Cassuto
J P
JP
Moreau
J
J
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002047:Buprenorphine / Q000627:therapeutic use*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009294:Narcotics / Q000627:therapeutic use*; D010349:Patient Compliance; D015819:Substance Abuse, Intravenous / Q000188:drug therapy* / Q000523:psychology; D011795:Surveys and Questionnaires
D019380:Anti-HIV Agents; D009294:Narcotics; D002047:Buprenorphine